Processa Pharma rises on positive results from early-stage cancer therapy trial

Processa Pharmaceuticals

01/11/2022 15:43

** Shares of biotechnology firm Processa Pharmaceuticals
 PCSA.O  up 8.3% at $2.29
    ** Co says a dosing regimen has been identified in
early-stage trial of its cancer treatment  urn:newsml:reuters.com:*:nGNXkVmTf
    ** Processa will meet with FDA in 2023 to confirm that the
design of the mid-stage trial conforms with the FDA's oncology
drug dosing initiative
    ** "We plan to use a Phase 2B trial to determine which
regimens provide this improved efficacy-safety profile over
present therapy.." - David Young, President and CEO of Processa
    ** In 2023, Processa plans to begin enrolling patients into
the midstage trial 
    ** Including the gains in the session, stock has 54.8% of
its value so far this year
 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((nandhini.srinivasan@thomsonreuters.com))